Lexicon Pharmaceuticals (LXRX) Change in Receivables (2010 - 2026)
Lexicon Pharmaceuticals' (LXRX) quarterly Change in Receivables came in at $9.4 million in Q1 2026, up 1015.69% year-on-year from $842078.3 in Q1 2025, and up 18690.0% on a QoQ basis from $50000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Change in Receivables (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Change in Receivables data on file, last reported at $9.4 million in Q1 2026.
- On a quarterly basis, Change in Receivables rose 1015.69% year-over-year to $9.4 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 913.25% increase from a year earlier, with the FY2025 full-year figure at -$1.1 million, down 144.21% from the prior year.
- Change in Receivables for Q1 2026 stood at $9.4 million, up from $50000.0 in the prior quarter.
- Over the last five years, Change in Receivables for LXRX reached as high as $9.4 million in Q1 2026 and fell as low as -$1.0 million in Q1 2025.
- Historically, Change in Receivables has averaged $692058.8 across 5 years, with a median of $151000.0 in 2025.
- On a YoY basis, Change in Receivables climbed as much as 14200.0% in 2023 and fell as far as 6216.67% in 2023.
- Year by year, Change in Receivables stood at -$12000.0 in 2022, then soared by 5866.67% to $692000.0 in 2023, then fell by 16.47% to $578000.0 in 2024, then plunged by 91.35% to $50000.0 in 2025, then surged by 18690.0% to $9.4 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $9.4 million in Q1 2026, $50000.0 in Q4 2025, and $151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 979.13 Mn | 808.47 Mn | 20.99 Mn | 9.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.40 Mn |
| Mar 31, 2026 | 9.40 Mn |
| Dec 31, 2025 | 50,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Mar 31, 2025 | -1.03 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | 578,000.00 |
| Dec 31, 2024 | 578,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 516,000.00 |
| Mar 31, 2024 | 516,000.00 |
| Dec 31, 2023 | 692,000.00 |
| Dec 31, 2023 | 692,000.00 |